If you have been reading about angiotensin IV and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
In 2007, videos were shared on YouTube of alleged salvia users laughing uncontrollably, apparently unable to perform simple tasks or to communicate. In an interview published in the San Francisco Chronicle in June 2007, Daniel Siebert said that the videos "make salvia look like some horrible drug that makes people nuts and dangerous ..." and that it stops people from realizing "there are sensible ways to use something like this." Waco Representative Charles Anderson (R), who is sponsoring one of several bills to ban salvia in Texas, told colleagues at a legislative hearing about a video that depicts a salvia user behind the wheel of a car. "What we really worry about, is youngsters doing this and then getting in a vehicle or getting on a motorcycle or jumping in a pool somewhere." Michigan Representative Michael Sak (D) submitted a bill which proposed Schedule I classification of Salvia divinorum and salvinorin A. He said that if people had questions about the deleterious effects of salvia, they should go on YouTube to watch the videos. A reporter questioned Sak as to whether he had ever seen a "Girls Gone Wild" video, and whether that would incite him to make alcohol illegal (Sak replied that he hadn't yet had a chance to review the material).
More sophisticated gut absorption model can be used. In those models, additional compartments describe the various sections of the gut lumen and tissue. Intestinal pH, transit times and presence of active transporters can be taken into account .
The relative index of soil productivity during this time clearly appreciated for locust bean, as well as the accumulation of P and organic C compared with neem. Shade tolerance of other crops planted the near locust bean tree may present additional problems. In a 2-year experiment on shading, Parkia biglobosa was "found to have suppressive effects on vegetative growth and yield of pearl millet in both years." Eggplant yields were also suppressed by trees to between one third and one tenth of the yield in controlled plots, which themselves were damaged by rain. Despite this, chilli pepper yields (which were also affected by rain in the controlled plots) increased by up to 150% under the canopy of the locust bean tree.
==== Modern interpretations ==== The interpretation of dependent origination as mainly referring to mental processes has been defended by various modern scholars such as Eviatar Shulman and Collett Cox. Eviatar Shulman argues that dependent origination only addresses "the way the mind functions in samsara, the processes of mental conditioning that transmigration consists of." He further argues that it "should be understood to be no more than an inquiry into the nature of the self (or better, the lack of a self)." Shulman grants that there are some ontological implications that may be gleaned from dependent origination. However, he argues that at its core dependent origination is concerned with "identifying the different processes of mental conditioning and describing their relations". For Shulman, dependent origination does not "deal with how things exist, but with the processes by which the mind operates." Shulman argues that the general principle of dependent origination deals exclusively with the processes outlined in the lists of nidanas (not with existence per se, and certainly not with all objects). Shulman writes that seeing dependent origination as referring to the nature of reality in general "means investing the words of the earlier teachings with meanings derived from later Buddhist discourse" which leads to a misrepresentation of early Buddhism. Sue Hamilton presents a similar interpretation which sees dependent origination as showing how all things and indeed our entire "world" (of experience) are dependently originated through our cognitive apparatus.
Sources: en.wikipedia.org
=== Disease === Disease can arise if the host's protective immune mechanisms are compromised and the organism inflicts damage on the host. Microorganisms can cause tissue damage by releasing a variety of toxins or destructive enzymes. For example, Clostridium tetani releases a toxin that paralyzes muscles, and staphylococcus releases toxins that produce shock and sepsis. Not all infectious agents cause disease in all hosts. For example, less than 5% of individuals infected with polio develop disease. On the other hand, some infectious agents are highly virulent. The prion causing mad cow disease and Creutzfeldt–Jakob disease invariably kills all animals and people that are infected. Persistent infections occur because the body is unable to clear the organism after the initial infection. Persistent infections are characterized by the continual presence of the infectious organism, often as latent infection with occasional recurrent relapses of active infection. There are some viruses that can maintain a persistent infection by infecting different cells of the body. Some viruses once acquired never leave the body. A typical example is the herpes virus, which tends to hide in nerves and become reactivated when specific circumstances arise. Persistent infections cause millions of deaths globally each year. Chronic infections by parasites account for a high morbidity and mortality in many underdeveloped countries.
=== 3 June === A missile strike on Dnipro killed a two-year-old girl and wounded 22 people after it hit a two-story building. Five of them were reportedly children, seventeen people were hospitalized and several were believed to have been trapped under the rubble. Belgorod Oblast Governor Vyacheslav Gladkov said that two people were killed by Ukrainian shelling.
=== MAGNET designation === In 2008, Southern Ohio Medical Center became the first hospital in the tri-state region (Ohio, Kentucky, West Virginia) to earn Magnet Recognition from the American Nurses Credentialing Center. The Magnet Recognition Program recognizes healthcare organizations for quality patient care, nursing excellence and innovations in professional nursing practice. In 2011, less than 7% of hospitals in the United States were able to achieve Magnet Recognition. SOMC earned Magnet re-designation in 2013.
Sources: en.wikipedia.org
== Awards and honors == 2017, "From Discovery to Precision Medicine: Mass Spectrometry Through the Years and Beyond" at Pittcon 2017, a session focused on the contributions of Robert E. Finnigan 2008, Selected for "Legends of Environmental Chemistry" by American Chemical Society, ACS annual meeting, New York 1999, Instrumentation Hall of Fame (Charter Member) by Pittcon, American Chemical Society and Chemical Heritage Foundation 1994, Selected as a Pioneer in Development of Analytical Instrumentation by Pittsburgh Conference (Pittcon) and American Chemical Society 1980, Distinguished Service in Engineering, College of Engineering, University of Illinois 1975, Distinguished Alumni Award, Electrical and Computer Engineering Department, University of Illinois
== "4-4-3-2" balanced diet message == An integral and ubiquitous part of the program's message was the "4-4-3-2" balanced diet program, part of the standard USDA nutrition guidelines/recommendations promoted during the 1960s and 1970s. The use of dietary supplements was strongly discouraged; it was taught that all nutritional needs, including the proper intake of vitamins, minerals, fats and carbohydrates, could be adequately obtained solely by adhering to a balanced diet, with appropriate servings from the "basic four" food groups. This message was enthusiastically repeated by the children several times per episode. (The "basic four" food groups were updated by USDA in subsequent decades by the 1990s-era "Food Guide Pyramid", the later "MyPlate" and current (as of 2026) "New Pyramid" nutritional guidelines programs.)
Molecular cloning is the laboratory process used to produce recombinant DNA. It is one of two most widely used methods, along with polymerase chain reaction (PCR), used to direct the replication of any specific DNA sequence chosen by the experimentalist. There are two fundamental differences between the methods. One is that molecular cloning involves replication of the DNA within a living cell, while PCR replicates DNA in the test tube, free of living cells. The other difference is that cloning involves cutting and pasting DNA sequences, while PCR amplifies by copying an existing sequence. Formation of recombinant DNA requires a cloning vector, a DNA molecule that replicates within a living cell. Vectors are generally derived from plasmids or viruses, and represent relatively small segments of DNA that contain necessary genetic signals for replication, as well as additional elements for convenience in inserting foreign DNA, identifying cells that contain recombinant DNA, and, where appropriate, expressing the foreign DNA. The choice of vector for molecular cloning depends on the choice of host organism, the size of the DNA to be cloned, and whether and how the foreign DNA is to be expressed. The DNA segments can be combined by using a variety of methods, such as restriction enzyme/ligase cloning or Gibson assembly.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.